This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Zambon, A. Search for Related Content PubMed Articles by Zambon, A. Social Bookmarking                         What's this?

Reducing vascular risk in the diabetic patient: implications from the FIELD study

Centre for Atherosclerosis Prevention and Treatment, Clinica Medica 1, University of Padua, Italy.

The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study, involving 9, 795 patients with type 2 diabetes, is the largest study to date investigating the role of a lipid-modifying therapy in reducing cardiovascular risk in type 2 diabetes. Although the reduction in the primary end point (non-fatal myocar-dial infarction [MI] and coronary heart disease [CHD] death) did not reach statistical significance, fenofibrate treatment was associated with a significant reduction in total cardiovascular events, largely driven by reductions in non-fatal MI and revascularisation procedures.

Subgroup analyses demonstrated greater treatment effect in patients without prior cardiovascular disease than in those with established cardiovascular disease (relative risk reduction for CHD events of 25%, p=0.014 vs. a non-significant 8% increase, respectively; and for total cardiovascular events of 19%, p=0.004 vs. no effect). Differences in the magnitude of the reduction in cardiovascular risk between studies emphasise the importance of considering patient characteristics, such as duration of diabetes, concomitant lipid-modifying therapy, glycaemic control and prior cardiovascular disease, which may all influence treatment response.

Taking these factors into account, as well as the promising effects on microangiopathy observed in FIELD, suggests that fenofibrate may have a role as a well-tolerated treatment (most likely in combination with a statin) in patients with early stage type 2 diabetes without evidence of macrovascular disease.

Key Words: fenofibrate • FIELD study • cardiovascular risk • microvascular complications • statins

Diabetes and Vascular Disease Research, Vol. 3, No. 1 Suppl, S16-S20 (2006)
DOI: 10.1177/147916410600300105


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?